Orgenesis Inc.
Healthcare · Pharmaceutical Preparations · NV · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | |
|---|---|---|---|---|---|---|
| Revenue | $1.0M | $530,000 | $36.0M | $31.6M | $6.2M | $2.6M |
| Operating income | −$39.8M | −$53.6M | −$10.1M | −$16.8M | −$95.8M | $22.0M |
| Net income | −$48.2M | −$55.4M | −$14.9M | −$18.1M | $1.1M | $24.1M |
| Total assets | $1.4M | $14.6M | $90.9M | $59.8M | $77.7M | $92.5M |
| Total liabilities | $38.9M | $35.5M | $31.7M | $21.2M | $25.0M | $55.5M |
| Equity | −$37.5M | −$21.0M | $27.6M | $38.5M | $52.6M | $5.5M |
| EPS (diluted) | $11.44 | $19.08 | $0.59 | $0.74 | $-0.29 | $-1.77 |
| Shares out. | 34.3M | 27.5M | 24.8M | 24.2M | 18.4M | 15.6M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2024- Operating margin
- −3842.3%
- Net margin
- −4653.6%
- Return on equity
- 128.4%
- Return on assets
- −3565.1%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 2878.2%
- Debt / equity
- —
- Book value / share
- $-1.09
- Revenue growth (YoY)
- 95.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2024- Altman Z″ (distress)
- -868.26distress
- Accruals / assets
- −2301.2%clean
- Piotroski F-Score
- 3/9weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast. What these scores mean →
Signs
● 3 severe● 4 warning● 3 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗May 16, 2025
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2025
- NT 10-Qmissed a reporting deadline ↗May 15, 2024
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2024
- NT 10-Qmissed a reporting deadline ↗May 17, 2022
- NT 10-Qmissed a reporting deadline ↗Jul 17, 2018
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Neurocords LlcPassive (13G)Mar 14, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Material events
SEC Form 8-K · most recent- Director / officer changeMar 13, 2026
- Entered a material agreement · Unregistered equity saleJan 26, 2026
- Entered a material agreement · New financial obligationSep 16, 2025
- Director / officer changeAug 25, 2025
- Director / officer changeAug 19, 2025
- Other material eventAug 1, 2025
- Delisting / listing-standard noticeJun 6, 2025
- Other material eventApr 22, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.